April 5 (Reuters) - Novavax Inc NVAX.O :
* NOVAVAX INITIATES COVID-19 VACCINE CLINICAL TRIAL CROSSOVER
* NOVAVAX INC - CROSSOVER ALLOWS PARTICIPANTS TO CONTINUE IN TRIALS AND REMAIN BLINDED
* NOVAVAX INC - CROSSOVER ENSURES THAT ALL TRIAL PARTICIPANTS RECEIVE ACTIVE VACCINE
* NOVAVAX INC - SOUTH AFRICA AND UK CROSSOVER ARMS INITIATED; US/MEXICO PREVENT-19 CROSSOVER PLANNED
* NOVAVAX INC - ALL PARTICIPANTS IN UK AND U.S. PHASE 3 TRIALS WILL BE OFFERED OPPORTUNITY TO RECEIVE AN ADDITIONAL ROUND OF INJECTIONS
* NOVAVAX - PLANNING TO EXPAND TRIAL TO INCLUDE PEDIATRIC AND ADOLESCENT ARMS, WHICH ARE ALSO EXPECTED TO BEGIN IN Q2
* NOVAVAX INC - COMPANY IS ALSO PLANNING A CROSSOVER IN PREVENT-19 STUDY, FOR WHICH COMPANY EXPECTS TO READ OUT INITIAL CLINICAL DATA DURING Q2